New drug approval process : accelerating global registrations / edited by- Guarino, Richard A.

Contributor(s): Guarino, Richard A Material type: Text

TextLanguage: English Series: Drugs and the pharmaceutical sciencesPublication details: New York : Marcel Dekker, Inc., c2004. Edition: 4th edDescription: xiv, 635 p. : figures, tables, ill. ; 22 cmISBN: 0824750411 Hard bound; 9780824750411Subject(s): Drug Approval | Drug Evaluation | Clinical Trials as TopicDDC classification: 615.10973 Online resources: WorldCat details | Ebook Fulltext

Contents:

Part I : Regulatory practices and procedures of new drug, biologic and device development -- Drug development teams -- Nonclinical drug development -- The investigational new drug application and the investigator's brochure -- General considerations of the new drug application -- The new drug application, content and format -- Abbreviated and supplemental new drug applications -- The biologics license application -- Device legislation and application -- Orphan drugs -- Part II : Clinical research development -- Adverse experiences, adverse reactions, interactions of drugs -- Biostatistics in pharmaceutical product development -- Industry and FDA liasion -- Part III : Specific aspects in the process of new product submissions -- Chemistry, manufacturing, and control requirements of the NDA and ANDA -- Data presentation for FDA submissions -- Preparing for FDA inspections -- Technology change -- The common technical document for the registration of pharmaceutical for human use -- Part IV : Global applications of good clinical practices -- Obligations of the investigator, sponsor, monitor -- Instituitional review board -- Quality assurance -- Managing clinical trials -- The European union directive on good clinical parctice in clinical trials -- HIPAA -- Part V : Effective and new methodologies in expediting new product approvals in the US and European union -- Working with a CRO -- The evolving SMO in the US -- Accelerating new product approvals. TOC

Summary: Clarifying how to develop and market new drugs efficiently and economically for global markets, this text covers the emphasis on over-the-counter drugs in the long-range plans of many companies and discusses licence applications review boards.

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings ( 4 )
Title notes ( 5 )
Comments ( 0 )

Holdings
Item type	Current library	Collection	Call number	Copy number	Status	Barcode
E-Book	EWU Library E-book	Non-fiction	615.10973 NEW 2004 (Browse shelf(Opens below))		Not for loan
Text	EWU Library Reserve Section	Non-fiction	615.10973 NEW 2004 (Browse shelf(Opens below))	C-1	Not For Loan	19384
Text	EWU Library Circulation Section	Non-fiction	615.10973 NEW 2004 (Browse shelf(Opens below))	C-2	Available	19385
Text	EWU Library Circulation Section	Non-fiction	615.10973 NEW 2004 (Browse shelf(Opens below))	C-3	Available	19386

Total holds: 0

Browsing EWU Library shelves, Shelving location: Circulation Section Close shelf browser (Hides shelf browser)

Previous								Next
Previous	615.1078 SIP 1997 Pharmacology laboratory manual :	615.1078 SIP 1997 Pharmacology laboratory manual :	615.10973 NEW 2004 New drug approval process :	615.10973 NEW 2004 New drug approval process :	615.13 COO 1975 Cooper and Gunn's dispensing for pharmaceutical students /	615.13 COO 1975 Cooper and Gunn's dispensing for pharmaceutical students /	615.13 COO 1975 Cooper and Gunn's dispensing for pharmaceutical students /	Next

Includes Bibliographical References and Index.

Part I : Regulatory practices and procedures of new drug, biologic and device development --
Drug development teams --
Nonclinical drug development --
The investigational new drug application and the investigator's brochure --
General considerations of the new drug application --
The new drug application, content and format --
Abbreviated and supplemental new drug applications --
The biologics license application --
Device legislation and application --
Orphan drugs --
Part II : Clinical research development --
Adverse experiences, adverse reactions, interactions of drugs --
Biostatistics in pharmaceutical product development --
Industry and FDA liasion --
Part III : Specific aspects in the process of new product submissions --
Chemistry, manufacturing, and control requirements of the NDA and ANDA --
Data presentation for FDA submissions --
Preparing for FDA inspections --
Technology change --
The common technical document for the registration of pharmaceutical for human use --
Part IV : Global applications of good clinical practices --
Obligations of the investigator, sponsor, monitor --
Instituitional review board --
Quality assurance --
Managing clinical trials --
The European union directive on good clinical parctice in clinical trials --
HIPAA --
Part V : Effective and new methodologies in expediting new product approvals in the US and European union --
Working with a CRO --
The evolving SMO in the US --
Accelerating new product approvals. TOC

Clarifying how to develop and market new drugs efficiently and economically for global markets, this text covers the emphasis on over-the-counter drugs in the long-range plans of many companies and discusses licence applications review boards.

Pharmacy

Abdul Gani

There are no comments on this title.

to post a comment.